Entry Decisions in the Generic Pharmaceutical Industry
利用1984-1994年所有仿制药进入数据，分析异质性潜在进入者的市场选择，发现组织经验、市场规模、医院销售和慢性病治疗产品吸引更多进入，但无法判断进入效率。
Data on all generic drug entries in the period 1984-1994 are used to estimate which markets heterogeneous potential entrants will decide to enter. I find that organizational experience predicts entry. Firms tend to enter markets with supply and demand characteristics similar to the firm's existing drugs. Larger revenue markets, markets with more hospital sales, and products that treat chronic conditions attract more entry. The simultaneous nature of entry leads to an additional interpretation: specialization is profitable because of the severe risk to profits when a market is overentered. However, I am unable to make any conclusions about the efficiency of entry decisions.